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Abstract
Mood-related disorders, including depression and anxiety, are prevalent among children and
adolescents. This poses a public health challenge, given their adverse impact on these young
populations. Treatment with the selective serotonin reuptake inhibitor fluoxetine (FLX) is the
first line of pharmacological intervention in pediatric patients suffering from affect-related
illnesses. Although the use of this antidepressant has been deemed efficacious in the juvenile
population, the enduring neurobiological consequences of adolescent FLX exposure are not well
understood. For this reason, we explored for persistent molecular adaptations, in the adult
hippocampus, as a function of adolescent FLX pretreatment. To do this, we administered FLX
(20 mg/kg/day) to male C57BL/6 mice during adolescence (postnatal day [PD] 35-49). Twentyone days later (PD70), whole hippocampal tissue was dissected. We then incorporated the
quantitative real-time reverse transcription polymerase chain reaction (qPCR) approach to assess
changes in the expression of genes associated with major intracellular signal transduction
pathways, including the extracellular signal-regulated kinase (ERK), the phosphatidylinositide-3kinase (PI3K)/AKT pathway, and the wingless (Wnt)-dishevelled-GSK3B signaling cascade.
Our results show that FLX treatment results in long-term dysregulation of mRNA levels across
numerous genes from the ERK, PI3K/AKT, and Wnt intracellular signaling pathways, along
with increases of the transcription factors CREB, ΔFosB, and zif268. Lastly, FLX treatment
resulted in persistent increases of transcripts associated with cytoskeletal integrity (b-actin) and
caspase activation (DIABLO), while decreasing genes associated with metabolism (fucose
kinase) and overall neuronal activation (c-Fos). Collectively, these data indicate that adolescent
FLX exposure induces persistent alterations in hippocampal gene expression in adulthood, thus,
questioning the safety of early-life exposure to this antidepressant medication.
vi
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Chapter 1: Introduction
Depression and anxiety disorders are major health problems worldwide, given their
association with significant disability and mortality, as well as reduced quality of life (Bandelow
& Michaelis, 2015; Kessler & Bromet, 2013). The occurrence of mood-related illnesses is highly
prevalent in younger populations, with an incidence of depressive disorders increasing from 1%
in childhood up to 8% in adolescence, and anxiety disorders affecting up to 20% of the pediatric
population (Birmaher et al., 2003; Merikangas et al., 2010). To make matters worse, if left
untreated, these neuropathologies increase the risk of substance abuse, suicide attempts, impaired
social function, and the development of comorbid neuropsychiatric conditions in adulthood (Pine
et al., 1998; Thapar et al., 2010; Tiller, 2013; Wehry et al., 2015).
Despite the high incidence and negative health impact of mood-related disorders in the
pediatric population, pharmacological treatment options are severely limited (Birmaher et al.,
2003; Bylund & Reed, 2007). Fluoxetine (FLX), a selective serotonin reuptake inhibitor (SSRI),
is widely prescribed for the management of both depression and anxiety, and is approved by the
Food and Drug Administration for use in children and adolescents (Jane Garland et al., 2016;
Perez-Caballero et al., 2014). However, the prescription of SSRIs, particularly FLX, in young
patients remains controversial, as several studies have demonstrated limited efficacy, as well as
age-related differences in treatment response (Bowman & Daws, 2019; Bridge et al., 2007;
Kronenberg et al., 2007). Furthermore, because brain development continues into adolescence
(Konrad et al., 2013), exposure to psychotropic medications during this sensitive period may
have enduring consequences (Alcantara et al., 2014; Garcia-Carachure et al., 2020; Olivier et al.,
2011). Indeed, accumulating evidence from animal studies indicate that exposure to FLX results
in adverse neurobehavioral effects that persist into later adulthood, including memory
1

impairment (Flores-Ramirez et al., 2019; Sass & Wortwein, 2012), altered drug-seeking behavior
(Flores-Ramirez et al., 2018; Iñiguez et al., 2015), and decreased reactivity to inescapable stress
(Airan et al., 2007; Iñiguez, Alcantara, et al., 2014; Iñiguez et al., 2010; Karpova et al., 2009).
The primary mechanism of action of SSRI medications is to block the uptake activity of the
serotonin transporter, indirectly increasing global levels of serotonin, an effect that occurs rather
quickly (Bowman & Daws, 2019; Trivedi et al., 2006). However, therapeutic response to SSRI
treatment in patients usually takes several weeks, indicating that intracellular signaling molecules
downstream of serotonergic receptors underlie this delayed effect (Kroeze et al., 2015).
Experimental evidence from adult normal animals indicate that brain-derived neurotrophic factor
(BDNF), and several of its intracellular targets such as the mitogen-activated protein kinase
(MAPK) extracellular signal-regulated protein kinase (ERK)-1/2, phosphoinositide-3 kinase
(PI3K)/protein kinase-b (AKT) signaling molecules, and members of the wingless (Wnt) and
phospholipase-c-gamma-1 (PLCϒ1) cascades, play a role in mediating the therapeutic effects of
SSRIs (Bjorkholm & Monteggia, 2016; Duman & Monteggia, 2006; Freitas et al., 2013; Zhou et
al., 2016). Nevertheless, there is a dearth of research addressing the status of intracellular
signaling pathways as a function of early-life FLX exposure in adulthood. In order to address this
gap in the literature, the goal of this thesis is to examine the potential long-lived molecular
impact of adolescent FLX exposure on hippocampal gene expression in adulthood, using
C57BL/6 male mice as a model system. We focus on the hippocampus, given that this is a brain
region that is implicated in the etiology of affect-related illnesses (Airan et al., 2007; Cha et al.,
2016; Persson et al., 2014), the expression of drug-seeking behavior (Hitchcock & Lattal, 2018;
Meyers et al., 2006), and in mediating the therapeutic action of SSRIs (Dale et al., 2016; Duric et
al., 2010).
2

Specific Aim of Master’s Thesis:
Aim 1: Evaluate whether adolescent FLX exposure alters gene expression in the hippocampus of
adult male mice. To accomplish this, we will evaluate mRNA from three major
intracellular signaling pathways, namely the ERK1/2, PI3K-AKT, and Wnt cascades, as
well as additional molecular players with diverse cellular functions including
metabolism, cell death, and overall membrane integrity (see Table 1 for full list of
genes).

Hypothesis: Previous work has shown that chronic FLX exposure increases mRNA of
members in the nerve growth family, namely BDNF, its receptor Tropomyosin receptor kinase B
(TrkB), as well as cAMP response element binding protein (CREB), in the rat hippocampus
(Nibuya, Nestler, & Duman, 1996). Additionally, signaling molecules downstream of BDNF
have also been shown to be upregulated by chronic antidepressant treatment (First et al., 2011; Li
& Jope, 2010). Yet, the developmental ramifications of this antidepressant-mediated mRNA
expression remain unknown. Therefore, our central hypothesis is that adolescent FLX exposure
will lead to dysregulated gene expression of intracellular signaling cascades and transcription
factors in the hippocampus of adult male mice.

3

Chapter 2: Materials and Methods
2.1 Animals
Postnatal day (PD)-28 male C57BL/6 mice were obtained from Charles River
Laboratories (Hollister, CA). Mice were maintained in an animal facility under controlled
humidity and temperature conditions (21-23°C). Mice were housed in clear polypropylene boxes
(3-4 per cage) containing wood shaving bedding, maintained on a 12:12 hr cycle (lights on at
700 hr), and were provided with water and food ad libitum. Experiments were conducted
following the National Institutes of Health Guide for the Care and Use of Laboratory Animals
(Council, 2003), and with approval of the Institutional Animal Care and Use Committee at The
University of Texas at El Paso (Protocol: A-201609-1).

2.2 Drug Treatment
Fluoxetine hydrochloride (FLX) was purchased from Spectrum Chemicals (Gardena,
CA), and was dissolved in distilled sterile water (vehicle; VEH). Animals received
intraperitoneal (IP) injections of either FLX or VEH using a volume of 2 ml/kg.

2.3 Experimental Design
A total of 24 male C57BL/6 mice were randomly assigned to receive VEH or FLX
treatment (n = 12 per group). Specifically, mice were injected with VEH or FLX (20 mg/kg/day)
for 15 consecutive days during PD35-49. Animals were then allowed a 21-day period without
drug administration and were subsequently euthanized once they reached adulthood (on PD70).
The selected timeframe of FLX administration (PD35–49) was chosen because it closely
resembles the human adolescent period (Abreu-Villaca et al., 2010; Andersen, 2003), while the
4

FLX dose (20 mg/kg/day) was selected due to its well-established antidepressant-like response in
animal models commonly adopted for the study of mood-related disorders (Englander et al.,
2005; Flores-Ramirez et al., 2019; Iñiguez et al., 2010; LaPlant et al., 2010; Surget et al., 2011).
A timeline of the experimental design is provided in Figure 1.

2.4 Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction
Gene expression is the biological process by which nuclear deoxyribonucleic acid (DNA)
transcribes into messenger ribonucleic acid (mRNA), and ultimately translates into functional
proteins (Crick, 1970). Measuring genetic expression can provide new information about the
amount of gene product (i.e., mRNA) present in a cell. For example, this approach can be used to
determine if an experimental manipulation (i.e. FLX pretreatment) has the potential to increase
or decrease the expression of genes of interest, in a specific brain region (i.e. the hippocampus).
One of the most precise gene quantification tools used in molecular biology is the quantitative
real-time reverse transcriptase Polymerase Chain Reaction (qPCR) method.
The qPCR technique analyzes the gene transcripts present in a sample of interest through
reverse transcription. First, isolated mRNA is purified and then homogenized with reverse
transcriptase

(DNA

polymerase

enzyme

that

transcribes

mRNA

into

DNA)

and

deoxyribonucleotides (nucleotides specific to DNA). This synthesis yields a single strand of
DNA complementary (cDNA) to the original mRNA template. Then, with the help of (1) primers
(short pieces of single-stranded DNA from target genes, that bind to the cDNA sequences in a
sample), (2) deoxynucleoside triphosphates (dNTPs; substrates of DNA nucleotides), (3) DNA
polymerase (DNAP; an enzyme that generates DNA molecules by assembling nucleotides), and
(4) fluorophore (a fluorescent chemical compound that binds to sample DNA and emits light
5

upon light excitation), single-stranded cDNA is reverse transcribed into a double-stranded DNA
(dsDNA) template of the target genes of interest. Lastly, qPCR is performed to amplify and
measure the dsDNA templates. Read-outs (SYBR Green fluorescence emitted by the dsDNA)
from the qPCR reaction are analyzed and fold-change (a change in expression of genes between
a control and an experimental group) is calculated (see section 2.4.3 below).

2.4.1 Strengths and Limitations of qPCR
A strength of the qPCR technique is the ability to quantify and measure specific
sequences of transcripts (i.e., specific gene sequences). During reverse transcription,
gene-specific primers can be utilized in place of random primers to increase the
specificity of the cDNA strand. The specific-primer approach also reduces the amount of
unspecific cDNA in a sample, thereby improving the read-outs of subsequent qPCR
amplification. Yet, another advantage of the qPCR method can be its ability to increase
cDNA yield with the use of random primers. Random priming maximizes the number of
cDNA templates produced, thereby increasing the number of subsequent qPCR reactions
that can be processed, making this a more economically viable option for exploratory
analysis. Overall, the results from qPCR analysis increase our understanding of the
transcriptional mechanisms of genes in a cell. However, conclusions regarding a cell’s
post-translational mechanisms cannot be made using this molecular technique.
A limitation of the qPCR method is the inability to detect and measure protein
quantities. Proteins, the byproducts of gene translation, carry out a diverse range of
functions within a cell (i.e., differentiation). Hence, protein detection is considered a
crucial step in determining the characteristics and molecular processes of specific cells.
6

While several molecular techniques, such as Western Blotting, can measure the total
protein levels of a sample, protein quantification cannot be achieved using qPCR in part
because of its starting material. Given that the purified mRNA (starting material) is
reverse transcribed into cDNA, the only end-product possible is dsDNA, not protein.
Moreover, those results can prove the existence of a gene in a tissue but cannot lead to
direct conclusions about levels of total or phosphorylated protein. Therefore,
interpretations about which specific proteins are present in a cell are limited to protein
quantification tools, such as immunoblotting techniques.

2.4.2 Experimental Procedure
Whole hippocampus was microdissected on dry ice and stored at -80°C until
assayed (Iñiguez et al., 2012). RNA isolation was carried out with RNEasy Micro kits
according to the manufacturer’s instructions (Qiagen; Austin, TX). RNA was then
reverse transcribed into cDNA, using the iScript cDNA synthesis kit (Bio-Rad; Hercules,
CA). qPCR was then conducted using a commercially available kit (RealMasterMix,
Eppendorf; Westbury, NY), running duplicate samples from each animal. Cycle threshold
(Ct) values were determined and changes in gene expression were analyzed by the ΔΔCt
method (Vialou et al., 2010), using GAPDH as housekeeping reference. The primer
sequences for the analyzed genes are displayed in Table 2.

7

2.4.3 ΔΔCt Method of Analyses for qPCR
The ΔΔCt method determines relative fold change. A ΔΔCt value is calculated
using Ct values obtained from the qPCR reaction. A Ct value represents the cycle number
at which the fluorescence emitted by the qPCR product from gene sample, is above
background levels. The Ct values of a housekeeping gene sample, such as GAPDH, is
also included in the qPCR analysis as a control, because its stably expressed across all
cell types and their gene expression is often not affected by pharmacological treatment
such as FLX.
The first step in a ΔΔCt calculation is to acquire the Ct value of every target gene
and housekeeping gene sample in a group. Also, since samples are loaded into the qPCR
plate in duplicates or triplicates, an average Ct value for each gene (target and
housekeeping), across experimental groups (VEH and FLX), needs to be calculated.
Ultimately, leading to four Ct group averages [target genes Ct (VEH), Ct (FLX) and
housekeeping genes Ct (VEH), Ct (FLX). Next, normalized (variation is removed via the
housekeeping gene values) Ct values (ΔCt) in the VEH and FLX groups are calculated
using the following equations: ΔCt(VEH) = Ct(TARGET

GENE)

– Ct(GAPDH), and ΔCt

(FLX)

=

Ct(TARGET GENE) – Ct(GAPDH). The difference between a normalized VEH and FLX group is
calculated using the following equation: ΔΔCt = ΔCt(FLX) – ΔCt(VEH). Finally, fold change
or changes in level of gene expression are calculated as followed: 2–ΔΔCt. The target genes
analyzed are displayed in Table 1.
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2.4.4 Troubleshooting qPCR
qPCR is highly prone to cross-contamination. To prevent this, working surfaces
should be sanitized with a DNA decontamination solution (such as DNAzap™) before
and after every qPCR protocol.
Negative controls, such as “No Template Controls” (NTC), can be also
incorporated in qPCR plate analysis to rule out any random and/or reagent contamination.
NTC wells are comprised of the qPCR master mix, RNAase free water, and primers, but
no DNA or mRNA templates. Therefore, amplification should not occur in an NTC
sample during the qPCR reaction. However, if for example the qPCR master mix happens
to be contaminated with an amplicon (a gene-specific sequence of nucleotides that
elongate cDNA) or any other DNA contaminant then amplification will be detected,
ultimately leading to false positive results. To resolve this, a new mixture of the reagents
should be prepared in a separate and decontaminated working space.

2.5 Data Analysis
Experimental animals were randomly assigned to receive VEH or FLX during
adolescence. Data were analyzed using two-tail Student’s t tests. Data are presented as ± standard
error of the mean (SEM), and statistical significance was defined as p<0.05.

9

Chapter 3: Results
3.1 Adolescent FLX exposure increases gene expression of the MAPK pathway in the adult
hippocampus
Figure 2 displays the effects of juvenile FLX exposure (PD35-49) on the expression of
multiple genes within the MAPK signaling pathway in adulthood (PD70). When compared to
VEH-pretreated controls (n = 12) adult mice pretreated with FLX during adolescence (n = 12)
displayed increases in MEK1 (t22 = 3.60, p = 0.0016; Fig. 2B), MEK2 (t22 = 6.48, p<0.0001; Fig.
2C), ERK1 (p = 0.06; Fig. 2D), ERK2 (t22 = 5.40, p<0.0001; Fig. 2E), and p90RSK (t22 = 6.11,
p<0.0001; Fig. 2F). However, no differences in BDNF (p>0.05; Fig. 2A) mRNA were noted
between FLX and VEH pretreated mice.

3.2 Adolescent FLX exposure increases gene expression of transcription factors in the adult
hippocampus
Figure 3 shows the effects of juvenile FLX treatment (PD35-49) on adult hippocampal
expression (PD70) of transcription factors, on which several signaling pathways are known to
converge. When compared to VEH-pretreated controls (n = 12), adult mice pretreated with FLX
during adolescence (n = 12) displayed significant increases in CREB (t22 = 6.40, p<0.0001; Fig.
3A), Zif268 (t22 = 5.14, p<0.0001; Fig. 3B), and ΔFosB (t22 = 3.16, p = 0.0045; Fig. 3C).

3.3 Adolescent FLX exposure increases gene expression of the IRS2/PI3K/AKT pathway in the
adult hippocampus
Figure 4 shows the effects of adolescent FLX treatment (PD35-49) on hippocampal
expression of genes from the IRS2/PI3K/AKT pathway in adult male mice (PD70). We found
10

that when compared to VEH-pretreated controls (n = 12), adult mice pretreated with FLX during
adolescence (n = 12) displayed significant increases in IRS2 (t22 = 4.18, p = 0.0004; Fig.4A),
PI3K (t22 = 2.48, p = 0.0212; Fig. 4B), PDK (t22 = 3.62, p = 0.0015; Fig. 4C), AKT1 (t22 = 4.25, p
= 0.0003; Fig. 4D), and GSK3β-1 (t22 = 2.75, p = 0.0114; Fig. 4E).

3.4 Adolescent FLX exposure alters genes from the Wnt signaling pathway in the adult
hippocampus
Figure 5 displays the effects of juvenile FLX treatment (PD35-49) on hippocampal
expression of genes within the Wnt signaling pathway in adulthood (PD70). When compared to
VEH-pretreated controls (n = 12), adult mice pretreated with FLX during adolescence (n = 12)
displayed significant decreases in Wnt1 (t22 = 3.63, p = 0.0014; Fig. 5A), without changes in
Wnt5a (p>0.05; Fig. 5B). Conversely, adolescent FLX pretreatment increased mRNA levels of
DVL2 (t22 = 5.56, p<0.0001; Fig. 5D), but not DVL1 (p>0.05; Fig.5C) or DVL3 (p>0.05; Fig.
5E). Likewise, adolescent FLX history increased the expression of β-catenin (t22 = 6.73,
p<0.0001; Fig. 5F), PLCγ1 (t22 = 4.71, p = 0.0001; Fig. 5G), and CaMKIIα (t22 = 2.33, p =
0.0291; Fig. 5H) in the hippocampus of adult mice.

3.5 Adolescent FLX exposure alters the expression of hippocampal genes with diverse cellular
functions in adulthood
Figure 6 displays the effects of adolescent FLX treatment (PD35-49) on the expression
of hippocampal genes with various intracellular functions in adulthood (PD70). Here, when
compared to VEH-pretreated controls (n = 12), adult animals pretreated with FLX during
adolescence (n = 12) displayed increased gene expression of DIABLO (t22 = 2.35, p = 0.0279;
11

Fig. 6A) and β-actin (t22 = 4.69, p = 0.0001; Fig 6B). Conversely, adolescent FLX history
significantly decreased expression of fucose kinase (FUK; t22 = 2.35, p = 0.0278; Fig. 6C) and
the immediate early-gene c-Fos (t22 = 3.38, p = 0.0027; Fig. 6D), without affecting mRNA levels
of either BAD (p>0.05; Fig. 6E) or sonic hedgehog (SHH, p>0.05; Fig. 6F).
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Chapter 4: Discussion
4.1 Summary
Accumulating preclinical evidence suggests that juvenile exposure to FLX leads to
complex behavioral side effects in adulthood; wherein rodents display attenuated responses to
inescapable stress (Airan et al., 2007; Iñiguez, Alcantara, et al., 2014; Karpova et al., 2009)
along with enhanced drug-seeking behavior (Iñiguez et al., 2015), among other phenotypes
(Olivier et al., 2011). Collectively, these enduring FLX induced alterations suggest that
ontogenic exposure to SSRIs may render the organism in need of subsequent antidepressant reexposure in later life to normalize behavior (Iñiguez et al., 2010; Karpova et al., 2009). Thus, the
goal of this thesis was to explore the persistent molecular alterations that may result as a function
of adolescent SSRI exposure in the adult hippocampus, given that this brain region modulates
responses to stress and reward-seeking behavior under normal conditions (Duric et al., 2010;
Meyers et al., 2003). Specifically, we evaluated whether FLX administration during adolescence
exerts long-term changes in adult hippocampal expression of genes belonging to several major
intracellular signaling pathways involved in neuronal growth and survival, including the
ERK1/2, IRS2/PI3K/AKT, and Wnt cascades, as well as genes with varied cellular functions,
including modulation of calcium signaling (Ca++/calmodulin-dependent protein kinase II
[CamKIIα]), mitochondrial homeostasis (Direct IAP binding protein with low pI [DIABLO],
and Bcl2-associated agonist of cell death [BAD]), metabolism (fucose kinase [FUK]), neuronal
survival (sonic hedgehog [SHH]), and cytoskeletal assembly (β-actin).
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4.2 Adolescent FLX exposure increases MAPK-related gene expression in the adult
hippocampus
BDNF is a central component of several intracellular signaling cascades, given its ability
to initiate signal transduction of different pathways, including those mediated by MAPK, AKT,
and Wnt-disheveled (DVL)-phospholipase C gamma (PLCγ1) signaling (Bjorkholm &
Monteggia, 2016). Previous studies have established BDNF as a key molecule in mood-related
pathologies, and thus, signaling pathways modulated by this neurotrophic factor can be
influenced by the actions of antidepressant drugs, including SSRIs (Autry & Monteggia, 2012;
Castren & Rantamaki, 2010). Acute FLX has been shown to alter multiple intracellular signaling
pathways (Alcantara et al., 2014; Warren et al., 2011; Yan et al., 2020), and early-life FLX
exposure induces long-term increases in the expression of hippocampal BDNF and its main
receptor TrkB (Karpova et al., 2009). Thus, we evaluated BDNF mRNA levels within the adult
hippocampus as a function of adolescent FLX exposure. Surprisingly, we did not find changes in
hippocampal BDNF mRNA (Fig. 2A) – likely due to the differences in the age window of FLX
pre-exposure (prepubertal [PD4-21] vs. adolescence [PD35-49]) as well as the promoter
specificity of BDNF assessed between the studies. Yet, we found an overall upregulation in
mRNA levels of the downstream MAPK signaling pathway (MEK1/2-ERK1/2-p90RSK) 21days post FLX exposure (Fig. 2B-F). This is an intriguing finding that now bridges hippocampal
neurobiological alterations with the persistent FLX-dependent behavioral effects previously
reported (Homberg et al., 2011). For example, adult male mice pre-exposed with FLX during
adolescence display enhanced preference for rewarding substances like sucrose (Iñiguez et al.,
2010) and cocaine (Iñiguez et al., 2015), mimicking the functional role of hippocampal ERK
signaling that is observed in adult animals displaying drug-seeking behavior (Tropea et al.,
14

2008). Further supporting the relationship between ERK and facilitated reward, we found
persistent FLX induced elevations of CREB, ΔFosB, and Zif268 (Fig. 3A-C); transcription
factors downstream of ERK that have been associated with cocaine-seeking behavior (Gajewski
et al., 2019; Hearing et al., 2010; Tropea et al., 2008). Interestingly, while psychological and/or
physical stress precipitates drug preference (Fosnocht et al., 2019; Garcia-Carachure et al., 2020;
McLaughlin et al., 2006), in a paradoxical manner, juvenile FLX history leads to persistent
decreases in responsivity to inescapable stress challenges – since FLX pretreated rodents do not
exhibit the characteristic social avoidance induced by repeated social defeat stress (Iñiguez,
Alcantara, et al., 2014) or enhanced immobility on the forced swim test (Iñiguez et al., 2010;
Karpova et al., 2009). Thus, the enduring FLX induced increases of hippocampal MAPK
signaling (Fig. 2), and its downstream transcription factors (Fig. 3), capture both the facilitated
drug-seeking phenotype, as well as the resilient-like properties, that these molecules induce in
adult animals under normosensitive conditions (Duric et al., 2010; Iñiguez et al., 2019). Yet,
here, we report that juvenile SSRI pre-exposure leads to hippocampal MAPK upregulation in
adulthood, a critical finding that provides a potential molecular mechanism for the behavioral
alterations observed as a function of adolescent FLX history. Interestingly, previous work from
our laboratory shows decreases in ERK-signaling within the ventral tegmental area of the
midbrain in adult male rodents pre-exposed to FLX during adolescence (Iñiguez, Alcantara, et
al., 2014). Along with this earlier work, we now show that juvenile antidepressant exposure
changes MAPK signaling differentially across different brain regions in adulthood; with
adolescent FLX exposure resulting in long-term decreases of ERK in the ventral tegmental area,
while increasing it in the hippocampus (Fig. 2) – an important finding that uncovers long-term
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molecular circuit-based alterations between reward related regions (i.e., ventral tegmental area)
and the hippocampal formation.

4.3 Adolescent FLX exposure alters AKT- and Wnt-related hippocampal gene expression in
adulthood
Given that insulin receptor substrate (IRS)-2 modulates synaptic plasticity within the
hippocampus (Martin et al., 2012), as well as responses to antidepressant medications and drugs
of abuse (Glombik et al., 2017; Iñiguez et al., 2008; Russo et al., 2007), we further evaluated the
enduring impact of adolescent FLX on IRS2 and its downstream signaling components,
including PI3K, PDK, AKT, and glycogen synthase 3 beta-1 (GSK3β-1). Here, adolescent FLX
history increased the mRNA levels of these genes in the adult hippocampus (Fig.4). This
prolonged FLX induced upregulation of the AKT signaling cascade is consistent with previous
work demonstrating that adult male rodents pre-exposed to FLX during adolescence display
long-lasting prophylactic phenotypes (Iñiguez et al., 2010). In other words, the persistent
increases in AKT signaling, as a function of FLX history, mediates resilient-like behavioral
responses on preclinical tests of despair, as well as in postmortem tissue of depressed patients
that were taking antidepressants at the time of death (Krishnan et al., 2008). Likewise, we
evaluated molecular markers related to the Wnt pathway, given that deregulation of this
signaling cascade has been proposed to underlie aspects of major depression and antidepressant
efficacy (Wilkinson et al., 2011), as well as responses to cocaine (Dias et al., 2015). In this case,
adolescent FLX pre-exposure decreased Wnt1, but not Wnt5a (Fig. 5A-B) hippocampal mRNA
levels in adulthood. Conversely, we found that adolescent FLX pretreatment resulted in a
persistent upregulation of several downstream components of the Wnt canonical (β-catenin; Fig.
16

5F) and noncanonical (PLCγ1 and CaMKIIα; Fig. 5G-H) pathways. Specifically, FLX exposure
resulted in a lasting increase of DVL2 (but not DVL1 or DVL3; Fig. 5C-E), β-catenin (Fig.5F),
PLCγ1 (Fig.5G) and CaMKIIα (Fig.5H). Of note, PLCγ1 and CaMKIIα are both signaling
markers that crosstalk with the protein kinase C (PKC) cascade, and thus, it is likely that FLX
history de-regulates additional signaling pathways involved in plasticity, cell migration, and
neurogenesis (Abdolmaleki et al., 2020).

4.4 Adolescent FLX exposure alters hippocampal transcripts associated with neuronal
function/structure in adulthood
One of the interesting things about FLX is that it increases plasticity/neurogenesis
markers within the hippocampus, along with decreases in immobility on the forced swim test,
three weeks post antidepressant exposure (Airan et al., 2007) – thus, matching the persistent
resilient-like profile commonly reported in adult male mice and rats with juvenile FLX history
(Iñiguez, Alcantara, et al., 2014; Iñiguez et al., 2010; Karpova et al., 2009). Because the integrity
of the hippocampus plays a central role in affect-related disorders (Cha et al., 2016), we further
evaluated whether SSRI history would result in long-term changes of hippocampal genes
associated with neuronal growth (SHH; (Gonzalez-Reyes et al., 2019)), apoptosis (DIABLO,
BAD; (Troy et al., 2002)), cytoskeletal assembly (β-actin; (Chung, 2015)), metabolism (FUK;
(Angenstein et al., 1992; Popov et al., 1983)) as well as overall neuronal activation (c-Fos; (Gao
& Ji, 2009)). While no differences in SHH or BAD were noted between the groups, we found a
persistent increase in DIABLO and β-actin, along with decreases in FUK and c-Fos mRNA
expression (Fig. 6). Interestingly, these long-lived FLX induced transcriptional changes mimic
those induced by stress/injury insults; wherein rodents display increases in β-actin (P et al.,
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2012) and the release of proapoptotic mitochondrial intermembrane space proteins, like
DIABLO (X et al., 2005). Moreover, stress/injury insults impair memory performance, and since
FUK activity (Popov et al., 1983) and c-Fos expression (J et al., 2002) are positively correlated
with hippocampus-dependent memory performance, the long-term FLX-induced downregulation
of FUK and c-Fos, respectively, potentially contributes to the spatial memory impairment
observed in adult rodents with a history of FLX exposure during adolescence (Flores-Ramirez et
al., 2019). Collectively, these findings suggest that aberrant transcription of DIABLO, FUK, cFos, β-actin, as well as multiple intracellular pathways (i.e., ERK, AKT, Wnt) caused by
adolescent FLX exposure, may lead to altered neuronal plasticity/survival, and overall activation
of the adult hippocampus (Cowen, 2007; Varela-Nallar & Inestrosa, 2013); resulting in an
imbalance of information processing within brain circuits that modulate responses to rewards,
memory performance, and stress (Fig. 7). Although correlational, the results of this thesis may
provide a molecular signature to the complex behavioral profile exhibited by adult rodents
previously exposed to FLX during adolescence (Homberg et al., 2011; Iñiguez et al., 2015;
Iñiguez et al., 2010).

4.5 Limitations
A limitation of the present work is the exclusion of female rodents in our experimental
design, consequently reducing the interpretability of our data to the clinical setting – wherein
women, when compared to men, represent most of the patients prescribed with FLX for the
management of numerous illnesses including depression, eating disorders, anxiety, pain, and premenstrual dysphoric disorder (Hoffmann et al., 2014). As such, future investigations using
female rodents will be needed to assess whether similar or different patterns of hippocampal
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gene alterations, when compared to the present results in males, are expressed in adulthood as a
function of FLX pretreatment. Particularly, because juvenile FLX history results in differential
behavioral responses in adulthood to reward-related stimuli between the sexes – wherein males
display enhanced preference for drug rewards like cocaine (Iñiguez et al., 2015) while females
display a decrease in preference for the stimulant (Flores-Ramirez et al., 2018). Another caveat is
that the animals utilized in this investigation were not exposed to stress, a known risk factor for
the development of mood-related disorders. As such, future work is needed where adolescent
mice undergo similar FLX treatment along with stress models for the study of affect-related
illnesses (Iñiguez, Riggs, et al., 2014; N et al., 2020; Warren et al., 2020). Lastly, given that we
only evaluated mRNA expression in this study, additional experiments are needed to specifically
assess whether the gene expression findings translate to respective changes in hippocampal
protein levels.

4.6 Conclusion
We report that juvenile FLX exposure results in persistent gene expression changes
across several intracellular signaling cascades (ERK, AKT, and Wnt) that are implicated in
growth, plasticity, and the survival of neurons in the adult hippocampus of male C57BL/6 mice
(Iñiguez et al., 2020). These long-term FLX induced transcript changes provide a molecular link
to the complex behavioral phenotypes that result from early-life SSRI exposure, such as
enhanced drug-seeking behavior (Iñiguez et al., 2015) along with lower reactivity to inescapable
stress (Iñiguez, Alcantara, et al., 2014) and memory deficits (Flores-Ramirez et al., 2019; Sass &
Wortwein, 2012). Importantly, this work provides novel insight about the persistent hippocampal
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molecular consequences of adolescent exposure to the antidepressant FLX on adult behavior –
thus, questioning the safety of SSRI exposure during early stages of development.
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Table 1. Genes
Metabolism Factors:
•

β-actin (Beta-actin) – a member of the actin family; involved in cell motility, structure,
and integrity (RefSeq, 2015).

•

BAD (Bcl2-Associated Agonist of Cell Death) – positively regulates cell apoptosis by
reversing cell’s death repressor activity. It is known to be regulated by protein kinases
AKT and MAP kinase (RefSeq, 2019).

•

DIABLO (Direct IAP Binding Protein with Low pI) – mitochondrial protein that is
released into the cytosol in response to apoptotic stimuli (Verhagen et al., 2000)

•

FUK (Fucose Kinase) – this enzyme catalyzes the first step in the utilization of free Lfucose (thought to mediate inflammation, as well as metastasis) in glycoprotein and
glycolipid synthesis (Miller et al., 2005).

•

GAPDH (Glyceraldehyde 3-Phosphate Dehydrogenase) – a housekeeping gene that
plays an essential role in cell glycolysis (Barber et al., 2005).

•

SHH (Sonic Hedgehog) – important in the maintenance of the structure and overall
integrity of neuronal cells (Herzog et al., 2003)

Mitogen Activated Protein Kinase (MAPK) Pathway:
•

BDNF (Brain Derived Neurotrophic Factor) – involved in the growth, differentiation,
and survival of specific types of developing neurons both in the central- and peripheralnervous system. Involved in regulating synaptic plasticity in the CNS (RefSeq, 2015).

•

ERK1 (Extracellular Signal-Regulated Kinase 1) – also known as Mapk3, regulates
various cellular processes, including proliferation, differentiation, and cell cycle
progression in response to a variety of extracellular signals (RefSeq, 2008)

•

ERK2 (Extracellular Signal-Regulated Kinase 2) – also known as Mapk1, is involved
in cell proliferation, differentiation, transcription regulation, and development (RefSeq,
2014)

•

MEK1 (Mitogen-Activated Protein Kinase Kinase 1) – involved in the phosphorylation
of MAPK3/ERK1 and MAPK1/ERK2 and aids in the binding of extracellular ligands
(i.e., growth factors) to their cell-surface receptors (RefSeq, 2008)

•

MEK2 (Mitogen-Activated Protein Kinase Kinase 2) – an essential component of the
MAPK signaling pathway, known to play a role in mitogen growth factor signal
transduction (RefSeq, 2008)

•

p90RSK (phospho-90 kDa Ribosomal Kinase; MAPK Activated Protein Kinase 2) –
part of the MAPK signaling cascade as a direct downstream effector of ERK1/2 (Lin,
White & Hu, 2019)

•
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Nuclear Transcription Factors:
•

c-Fos (FBJ Murine Osteosarcoma Viral Oncogene Homolog) – an immediate early gene
involved in cell activation, proliferation, differentiation, and survival (RefSeq 2008).

•

CREB (cAMP Response Element-Binding Protein) – a cellular transcription factor that
plays a role in neuronal plasticity, long-term memory formation, and is integral in the
formation of spatial memory (Silva et al., 1998).

•

ΔFosB (DeltaFosB) – a member of the Fos family of transcription factors whose role is
commonly implicated in the development addiction- and depression-related behaviors
(Nestler, Barrot, & Self, 2001)

•

Zif268 (Zinc Finger Protein 268) – a transcriptional regulator protein, important for cell
differentiation and the modulation of apoptotic process (RefSeq, 2014)

Phosphoinositide 3-Kinase (PI3K)/ Protein Kinase B (AKT) Pathway:
•

AKT1 (Thymoma Viral Proto-oncogene 1/ Protein Kinase B) – a major downstream
effector of the phosphatidylinositol 3-kinase (PI3K) pathway that mediates the effects of
various growth factors (RefSeq, 2009).

•

GSK3β1 (Glycogen Synthase Kinase 3 Beta 1) – involved in energy metabolism,
inflammation, ER-stress, mitochondrial dysfunction, and apoptotic pathways (Plyte et
al., 1992).

•

IRS2 (Insulin Receptor Substrate 2) – a cytoplasmic signaling molecule that activates
neuronal growth and survival signaling pathways, such as PI3K/AKT, and modulates
synaptic plasticity within the hippocampus (Schubert et al., 2003; Martin et al., 2002)

•

PDK (Pyruvate Dehydrogenase Kinase) – mitochondrial regulatory enzyme known to
mediate the oxygen metabolism of the cell, as part of the PI3K/EKT pathway (Cerniglia
et al., 2015)

•

PI3K (Phosphoinositide 3-Kinase) – activates protein kinase B (AKT) as part of the
PI3K/AKT pathway. Also plays an important role in modulating several neuronal
functions, such as cell growth, survival, and intracellular trafficking (Cuesto et al., 2011)

Canonical Wingless/ Integrated (Wnt) Pathway:
•

β-catenin (Beta-catenin) – a subunit of the cadherin protein complex, acts as an
intracellular signal transducer in the Wnt signaling pathway, which controls cell growth
and differentiation during normal development (RefSeq, 2009).

•

CaMKIIα (Calcium/calmodulin-dependent Protein Kinase 2 Alpha) – this alpha
subunit of the CaMKII family is required for hippocampal long-term potentiation (LTP),
spine structural LTP, and spatial learning (Silva et al., 1992).

•
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Canonical Wingless/ Integrated (Wnt) Pathway:
•

DVL1 (Dishevelled-1); DVL2 (Dishevelled-2); DVL3 (Dishevelled-3) – members of the
Dishevelled (Dsh) family, implicated in the regulation of canonical (involving βcatenin) and non-canonical Wnt signaling, specifically the transduction of the Wnt
signal to down-stream effectors (Komiya & Habas, 2008).

•

PLCγ1 (Phospholipase-C Gamma 1) – cell growth factor important for cell growth, cell
migration, and apoptosis. In neuronal cells, it is involved in actin cytoskeleton
organization and synaptic plasticity (Kang et al., 2020)

•

Wnt1 (Wingless-Type MMTV Integration Site Family, Member 1) – extracellular
protein, part of the Wnt/canonical signaling pathway, involved in cytokine-, frizzledbinding, and protein domain specific binding activity (Castelo-Branco et al., 2003)

•

Wnt5a (Wingless-Type MMTV Integration Site Family, Member 5A) – part of the Wnt
signaling pathway involved in several processes, including the generation of neurons
and hormonal response (Lange et al., 2006)
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Table 2. Primer sequences
Gene

Forward primer

Reverse primer

AKT1
5’-ATGAACGACGTAGCCATTGTG-3’
5’-TTGTAGCCAATAAAGGTGCCAT-3’
BAD
5’-AAGTCCGATCCCGGAATCC-3’
5’-GCTCACTCGGCTCAAACTCT-3’
BDNF
5’-GAAGAGCTGCTGGATGAGGAC-3’
5’-TTCAGTTGGCCTTTTGATACC-3’
β-actin
5’-AGTGTGACGTTGACATCCGTA-3’
5’-GCCAGAGCAGTAATCTCCTTCT-3’
β-catenin
5’-ATGGAGCCGGACAGAAAAGC-3’
5’-CTTGCCACTAGGGAAGGA-3’
CaMKIIα
5’-GTTCTCCGTTTGCACTAGG-3’
5’-TTCCCAGTTCCTCAAAGAGC-3’
c-Fos
5’-AACCGCATGGAGTGTGTTGTTCC-3’ 5’-TCAGACCACCTCGACAATGCATGA-3’
CREB
5’-AGTGACTGAGGAGCTTGTACCA-3’
5’-TGTGGCTGGGCTGAAC-3’
DIABLO
5’-TCCTGTACCTGTGACTTCACC-3’
5’-TCCTGTACCTGTGACTTCACC-3’
DVL1
5’-GGCGGAGACCAAAATCATC-3’
5’-GGACTTGAAGAAGAATTTGTAGGC-3’
DVL2
5’-GGCGGAGACCAAAATCATC-3’
5’-GGACTTGAAGAAGAATTTGTAGGC-3’
DVL3
5’-GCGAGACCAAGATCATCTACC-3’
5’-TCGTCGTCCATAGACTTGAAGA-3’
ERK1
5’-TCCGCCATGAGAATGTTATAGGC-3’ 5’-GGTGGTGTTGATAAGCAGATTGG-3’
ERK2
5’-GGTTGTTCCCAAATGCTGACT-3’
5’-CAACTTCAATCCTCTTGTGAGGG-3’
ΔFosB
5’-AGGCAGAGCTGGAGTCGGAGAT-3’
5’-GCCGAGGACTTGAACTTCACTCG-3’
FUK
5’-CTGGAGGTAAGGCAGAGACG-3’
5’-TGTGCAAGATGAGGATCCAG-3’
GAPDH
5’-AGGTCGGTGTGAACGGATTTG-3’
5’-GTAGACCATGTAGTTGAGGTCA-3’
GSK3β-1
5’-GACAAGCATTTAAGAACCGAGA-3’
5’-ACCAGGTAAGGTAGACCTACATC-3’
IRS2
5’-CTGCGTCCTCTCCCAAAGTG-3’
5’-GGGGTCATGGGCATGTAGC-3’
MEK1
5’-AAGGTGGGGGAACTGAAGGAT-3’
5’-CGGATTGCGGGTTTGATCTC-3’
MEK2
5’-GTTACCGGCACTCACTATCAAC-3’
5’-CCTCCAGCCGCTTCCTTTG-3’
PDK
5’-TCCTGGACTTCGGAAGGGATA-3’
5’-GAAGGGCGGTTCAACAAGTTA-3’
PI3K
5’-ACACCACGGTTTGGACTATGG-3’
5’-GGCTACAGTAGTGGGCTTGG-3’
PLCg1
5’-ATCCAGCAGTCCTAGAGCCTG-3’
5’-GGATGGCGATCTGACAAGC-3’
p90RSK
5’-CCATCACACACCACGTCAAG-3’
5’-TTGCGTACCAGGAAGACTTTG-3’
SHH
5’-AAAGCTGACCCCTTTAGCCTA-3’
5’-TTCGGAGTTTCTTGTGATCTTCC-3’
Wnt1
5’-CTCGCCACTCATTGTCTGTG-3’
5’-TTCCCAGGCTGGCTCTAATA-3’
Wnt5a
5’-CAACTGGCAGGACTTTCTCAA-3’
5’-CATCTCCGATGCCGGACT-3’
Zif268
5’-TCGGCTCCTTTCCTCACTCA-3’
5’-CTCATAGGGTTGTTCGCTCGG-3’
AKT1 – thymoma viral proto-oncogene 1/protein kinase b; BAD – Bcl2-associated agonist of cell death; BDNF –
brain derived neurotrophic factor; β-actin – beta-actin; β-catenin – beta-catenin; CaMKIIα – calcium/calmodulindependent protein kinase 2 alpha; c-Fos - FBJ Murine Osteosarcoma Viral Oncogene Homolog; CREB – cAMP
response element-binding protein; DIABLO - Direct IAP binding protein with low pI; DVL1 – dishevelled-1; DVL2
– dishevelled-2; DVL3 – dishevelled-3; ERK1 – extracellular signal-regulated kinase 1; ERK2 – extracellular
signal-regulated kinase 2; ΔFosB – DeltaFosB; FUK – fucose kinase; GAPDH – glyceraldehyde 3-phosphate
dehydrogenase; GSK3β-1 – glycogen synthase kinase3 beta 1; IRS2 – insulin receptor substrate 2; MEK1 –
mitogen-activated protein kinase kinase 1; MEK2 – mitogen-activated protein kinase kinase 2; PDK – pyruvate
dehydrogenase kinase; PI3K – phosphoinositide-3 kinase; PLCγ1 – phospholipase C, gamma 1; p90RSK – MAPKactivated protein kinase 2; SHH – sonic hedgehog; Wnt1 – Wingless-Type MMTV Integration Site Family, Member
1; Wnt5a – wingless-type MMTV integration site family, member 5A; Zif268 – zinc finger protein 268.
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Figure 1. Timeline of experimental procedures. Adolescent male C57BL/6 mice (N=24;
12/group) were exposed to fluoxetine (0 or 20 mg/kg/day) for 15 consecutive days (postnatal day
[PD] 35-49). Twenty-one days later (rest period), animals were euthanized (PD70) and
hippocampal tissue was collected for qPCR (quantitative real-time Polymerase Chain Reaction)
analysis.
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Figure 2. Effects of adolescent fluoxetine (FLX) exposure on the expression of hippocampal
genes from the intracellular MAPK signaling pathway in adulthood. FLX exposure resulted in
increased hippocampal expression of MEK1, MEK2, ERK1, ERK2, and p90RSK, but did not
alter BDNF levels, in adult mice. Data are presented as mean ± SEM. *p<0.05, yp=0.06 when
compared with control (VEH).
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Figure 3. Effects of adolescent fluoxetine (FLX) exposure on the expression of hippocampal
transcription factors in adulthood. FLX pretreatment induced significant increases in
hippocampal expression of CREB, Zif268, and ΔFosB. Data are presented as mean ± SEM.
*p<0.05 when compared to control (VEH).
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Figure 4. Effects of adolescent fluoxetine (FLX) treatment on the expression of hippocampal
genes from the IRS2/PI3K/AKT pathway in adulthood. Adolescent FLX pretreatment mediated
significant increases in hippocampal expression of IRS2, PI3K, PDK, AKT1, and GSK3β-1.
Data are presented as mean ± SEM. *p<0.05 when compared to control (VEH).
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Figure 5. Effects of adolescent fluoxetine (FLX) treatment on the expression of hippocampal
genes from the Wnt pathway in adulthood. Adolescent FLX pretreatment downregulated Wnt1,
while increasing DVL2, β-catenin, PLCγ1, and CaMKIIα. No changes in Wnt5a, DVL1, or
DVL3 were noted between the groups. Data are presented as mean ± SEM. *p<0.05, when
compared with control (VEH).
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Figure 6. Effects of adolescent fluoxetine (FLX) treatment on the expression of hippocampal
genes with diverse cellular functions in adulthood. Adolescent FLX treatment increased
DIABLO and b-actin, while decreasing FUK and c-Fos expression, without altering BAD or
Sonic hedgehog (SHH). Data are presented as mean ± SEM. *p<0.05, when compared with
control (VEH).
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Figure 7. Schematic representation of the long-lived impact of adolescent fluoxetine exposure
on hippocampal mRNA expression in adulthood. Exposure to fluoxetine during adolescence
(postnatal days 35-49) altered genes associated with major intracellular signaling cascades
(AKT/ERK/Wnt), transcription factors (ΔFosB, Zif268, CREB), apoptosis (DIABLO),
metabolism (FUK), as well as neuronal structure (β-actin) and activation (c-Fos) in adulthood
(postnatal day 70). [+] Significantly higher when compared to controls. [-] Significantly lower
when compared to controls.
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